Sorrentino v. Barr Laboratories, Inc.

397 F. Supp. 2d 418, 2005 U.S. Dist. LEXIS 26987, 2005 WL 2981779
CourtDistrict Court, W.D. New York
DecidedNovember 7, 2005
Docket6:05-cr-06144
StatusPublished
Cited by1 cases

This text of 397 F. Supp. 2d 418 (Sorrentino v. Barr Laboratories, Inc.) is published on Counsel Stack Legal Research, covering District Court, W.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Sorrentino v. Barr Laboratories, Inc., 397 F. Supp. 2d 418, 2005 U.S. Dist. LEXIS 26987, 2005 WL 2981779 (W.D.N.Y. 2005).

Opinion

DECISION AND ORDER

LARIMER, District Judge.

In Harbor Ins. Co. v. Schnabel Found. Co., 946 F.2d 930, 937 n. 5 (D.C.Cir.1991), cert. denied, 504 U.S. 931, 112 S.Ct. 1996, 118 L.Ed.2d 592 (1992), the Court of Appeals for the District of Columbia Circuit gave the “legal definition of chutzpah” as “a young man, convicted of murdering his parents, who argues for mercy on the ground that he is an orphan.” On a variation of that theme, this case presents a pro se plaintiff bringing a wrongful death suit for the loss of his wife, whom plaintiff was convicted of murdering in 2002. Defendant, Barr Laboratories, Inc. (“Barr”), has moved for summary judgment.

BACKGROUND

On March 16, 2002, plaintiff stabbed his wife to death in their home. Dkt.#23-6 at 1, 51. He was subsequently charged with second-degree murder. At trial, his attorney presented a defense of extreme emotional disturbance, based in part on plaintiffs use of the drug fluoxetine (more commonly known as Prozac), which had been prescribed for him by a physician to treat plaintiffs depression, along with “various [other] drugs,” including codeine that plaintiff “ha[d] left over from various operations,” and “a couple of glasses of wine” on the night of the murder. Trial Transcript (“Tr.”) (Dkt.#23-6) at 937-38.

In support of that defense, plaintiffs attorney presented expert testimony by a forensic psychologist and by a physician, both of whom testified about the effects on plaintiff of his misuse of fluoxetine (by taking it intermittently, in various doses, rather than a constant dosage at regular intervals), combined with the other drugs and alcohol that he had ingested on the day of the homicide. Tr. at 963-1020. The trial judge also instructed the jury on the affirmative defense of extreme emotional disturbance, which under New York law would have reduced plaintiffs crime to first-degree manslaughter if the jury found *421 that plaintiff had “acted under the influence of extreme emotional disturbance for which there was a reasonable explanation or excuse .... ” N.Y. Penal L. § 125.25(1)(a). Tr. at 1289-92.

The jury convicted plaintiff of second-degree murder on December 12, 2002. Tr. at 1334; Certificate of Conviction (Dkt.# 23-7). In so doing, the jury expressly found that plaintiff had not proved by a preponderance of the evidence that he had suffered from extreme emotional disturbance at the time of his wife’s death. Tr. at 1334. Plaintiffs conviction was affirmed on appeal. See People v. Sorrenti-no, 12 A.D.3d 1197, 785 N.Y.S.2d 260 (4th Dep’t), leave to appeal denied, 4 N.Y.3d 748, 790 N.Y.S.2d 661, 824 N.E.2d 62 (2004).

Plaintiff brought this action in June 2004. The complaint, which was filed in state court and removed to federal court based on diversity jurisdiction under 28 U.S.C. § 1332, alleges that Barr was the manufacturer of the fluoxetine that plaintiff was taking at the time of his wife’s murder. 1 Plaintiff alleges that among the side effects of fluoxetine are suicidal tendencies, aggression, and violent behavior. Plaintiff alleges that Barr knew about these side effects, but did not warn the public about them. Plaintiff also alleges that his “wife of eighteen years Angela Sorrentino was stabbed by Bernard Sorrentino due to [plaintiffs] taking Barr labratories [sic] drug (Fluoxetine.).” Complaint at 2.

In this lawsuit, plaintiff asserts a claim against Barr for product liability based on Barr’s failure to warn of the side effects of fluoxetine. Although the nature of his claimed damages is not exactly clear, it appears that he seeks damages for his current imprisonment, as well as damages for his children “for the loss of their Mother and Father.” Complaint at 4.

DISCUSSION

I. Collateral Estoppel

Barr moves for summary judgment on the ground that plaintiff is collaterally estopped from relitigating the issue of fluoxetine’s role in his wife’s death, based on the criminal jury’s rejection of his extreme-emotional-disturbance defense. Under New York law, which governs this diversity action, the doctrine of collateral estoppel “precludes a party from relitigating in a subsequent action or proceeding an issue clearly raised in a prior action or proceeding and decided against that party or those in privity, whether or not the tribunals or causes of action are the saihe.” Ryan v. New York Tel. Co., 62 N.Y.2d 494, 500, 478 N.Y.S.2d 823, 467 N.E.2d 487 (1984). It is well settled that collateral estoppel may bar a plaintiff from bringing an action in federal court pursuant to 42 U.S.C. § 1983. See Allen v. McCurry, 449 U.S. 90, 101 S.Ct. 411, 66 L.Ed.2d 308 (1980). It is equally clear that a prior criminal conviction can give rise to collateral estoppel in a subsequent civil action involving some of the same factual issues. See, e.g., Anonymous v. Dobbs Ferry Union Free School Dist., 19 A.D.3d 522, 797 N.Y.S.2d 120 (2d Dep’t 2005); In re Nora M., 300 A.D.2d 922, 923, 750 N.Y.S.2d 901 (3d Dep’t 2002).

“There are two requirements for the application of collateral estoppel to an issue: (1) there must be an identity of issue which has necessarily been decided in the prior action and is decisive of the *422 present. action, and (2) there must have been a full and fair opportunity to contest the decision now said to be controlling.” Burgos v. Hopkins, 14 F.3d 787, 792 (2d Cir.1994) (internal quotations and citations omitted); see also Schwartz v. Public Adm’r, 24 N.Y.2d 65, 298 N.Y.S.2d 955, 246 N.E.2d 725 (1969). The party seeking the benefit of collateral estoppel bears the burden of proving there is an identity of issue, whereas the party contesting its application bears the burden of proving that he did not have a full and fair opportunity to litigate the claims in the prior action. Khandhar v. Elfenbein, 943 F.2d 244, 247 (2d Cir.1991); D’Andrea v. Hulton, 81 F.Supp.2d 440, 443 (W.D.N.Y.1999).

To show an identity of issue, “the issue must have been material to the first action or proceeding and essential to the decision rendered therein ... and it must be the point actually to be determined in the second action or proceeding such that a different judgment in the second would destroy or impair rights or interests established by the first.” Ryan,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Crum & Forster Insurance v. Goodmark Industries, Inc.
488 F. Supp. 2d 241 (E.D. New York, 2007)

Cite This Page — Counsel Stack

Bluebook (online)
397 F. Supp. 2d 418, 2005 U.S. Dist. LEXIS 26987, 2005 WL 2981779, Counsel Stack Legal Research, https://law.counselstack.com/opinion/sorrentino-v-barr-laboratories-inc-nywd-2005.